News

Two patients have been dosed in a clinical trial testing BX004, a nebulized phage therapy designed to kill Pseudomonas aeruginosa, the most common cause of lung infections in people with cystic fibrosis (CF). The Phase 1b/2a trial (NCT05010577), which is funded by the Cystic Fibrosis Foundation and underway in…

The prevalence of cystic fibrosis (CF), used as an indicator of the number of CF carriers, was correlated with rates of COVID-19 and related mortality during the pandemic’s early stages across 37 different countries, a study showed. “This report suggests a possible contribution of the CFTR genetic profile of…

More frequent lung function tests in young people with cystic fibrosis (CF) markedly increased the diagnoses of pulmonary exacerbations — bouts of lung symptom worsening — leading to improved treatment and better lung function, a Brazilian study suggested. “The impact of such a simple initiative can be substantial and…

Treatment with the probiotic Vivomixx appeared to lead to healthful changes in the gut microbiome of cystic fibrosis (CF) patients in a small clinical trial, including six with CF-related…

A newly launched biotech company called Carbon Biosciences is aiming to develop lung-specific gene therapy vectors — vehicles to deliver genetic material directly into a cell — to help treat cystic fibrosis (CF). The company has $38 million in series A financing, funded in part by the Cystic…

Regular use of antibiotics to treat persistent infections is linked with hypersensitivity reactions in individuals with cystic fibrosis (CF), a new study has found. Specifically, “the risk is highly associated with the number of cumulative exposures to antibiotics and increasing age,” the researchers wrote. And intravenous, or into-the-vein, administration…

Using a machine learning approach based on genetic data, a trio of scientists at Scripps Research identified a region of the CFTR protein that is vital for its proper function, but is barely affected by existing cystic fibrosis (CF) treatments. Researchers described their findings in the study “…

The Lung Transplant Foundation is hosting a meeting with the U.S. Food and Drug Administration (FDA) with the intent of educating the agency and public about the challenges of living with bronchiolitis obliterans syndrome (BOS), a severe complication of lung transplants. “This is the first time that regulators and policymakers…

Treatment with the antibiotic azithromycin did not prevent the development of lung damage in infants with cystic fibrosis (CF), but was safe and lowered inflammation, hospital stays and antibiotic usage, according to data from a Phase 3 clinical trial. “Azithromycin treatment from diagnosis of cystic fibrosis after newborn…

When an initial antibiotic failed to improve lung function with a pulmonary exacerbation, switching antibiotics did not lead to greater gains among adults or children with cystic fibrosis (CF), a study found. “It appears clear that regardless of antibiotic choice, there is a subset of patients who will be slow…